Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
Emory University
Universitätsklinikum Hamburg-Eppendorf
Bayer
RenJi Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Masonic Cancer Center, University of Minnesota
University Hospital, Strasbourg, France
Children's Oncology Group
Shanghai Children's Medical Center
Emory University
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Birmingham
Novartis
Children's Oncology Group
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)